UpToDate®

UpToDate® and Oncology Times are collaborating to present select newly released UpToDate Oncology content synopses, such as the examples below. UpToDate is the premier evidence-based, clinical support resource used by oncology professionals and healthcare practitioners worldwide to make informed clinical decisions at the point of care. Please note that the examples below are accurate as of the month/year indicated next to each topic excerpt. To ensure you are accessing the most current clinical information, subscribe to UpToDate. For a limited time, you can receive an additional 30 days added to an annual or longer personal subscription term when you visit go.uptodate.com/ot30 and enter promo code OT30. This offer is valid through June 30, 2026. These abstracts can be found at www.uptodate.com/contents/whats-new-in-oncology. Tumor treating fields plus gemcitabine and nabpaclitaxel in locally advanced pancreatic adenocarcinoma (April 2026) The US Food and Drug Administration (FDA) approved tumor treating fields (TTFs), a non-invasive device worn on the skin that uses alternating electric fields to disrupt cancer cell proliferation, in combination with gemcitabine plus nabpaclitaxel for patients with locally advanced pancreatic cancer.1 This approval is based on a randomized trial of over 570 such patients in which the addition of TTFs to initial therapy with gemcitabine plus nabpaclitaxel improved overall survival (median 16 vs. 14 months), with a rate of any grade device-related skin irritation of 76%.2 Although we consider TTFs to be an option in the treatment of locally advanced pancreatic cancer, clinical experience is limited, and the need to wear TTFs for most of the day may impact patient compliance. Tumor debulking in combination with chemotherapy for multiorgan metastatic colorectal cancer (April 2026) For select patients with metastatic colorectal cancer (mCRC) and oligometastatic disease, local treatment of the metastases (such as surgery or radiation therapy [RT]), in combination with chemotherapy, provides a potentially curative option. However, there are limited data on this approach in patients with mCRC involving multiple organs. In a randomized trial of almost 400 patients with multiorgan mCRC (with ≥80% of disease burden amenable to tumor debulking) and no disease progression after initial chemotherapy, use of tumor debulking (with surgery, RT, and/or ablative therapy) in addition to chemotherapy did not improve overall survival (median 28 vs. 30 months) and increased toxicity.3 Based on these results, we do not offer tumor debulking to patients with multiorgan mCRC that is responsive to chemotherapy Neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab for resectable intrahepatic cholangiocarcinoma (April 2026) For patients with resectable intrahepatic cholangiocarcinoma, studies are evaluating the use of novel neoadjuvant systemic regimens before surgery to improve outcomes. In a randomized trial of approximately 180 patients with resectable intrahepatic cholangiocarcinoma at high risk for recurrence, at a median follow-up of 17 months, use of neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab (GOLP) prior to surgical resection improved event-free survival compared with surgery alone (median 18 vs. 9 months).4 The use of neoadjuvant GOLP remains investigational for localized resectable intrahepatic cholangiocarcinoma, as further long-term survival data are necessary. Pimicotinib in patients with tenosynovial giant cell tumor (March 2026) For patients with unresectable tenosynovial giant cell tumor (TGCT), studies are investigating systemic options such as pimicotinib, a tyrosine kinase inhibitor. In a randomized trial in 94 patients with unresectable and symptomatic TGCT, the overall response rate at 25 weeks with pimicotinib was 54% compared with 3% in the placebo group.5 Patients receiving pimicotinib also had clinically meaningful improvements in range of motion, stiffness, and pain. Grade ≥3 treatment-related adverse events were higher in patients treated with pimicotinib (29% vs. 3%). We await regulatory approval prior to the use of pimicotinib in patients with TGCT. Pralsetinib in RET fusion-positive advanced NSCLC (March 2026) Longer-term data on the RET inhibitor pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) are emerging. In the final analysis of a multicohort, open-label study in over 250 such patients, among those with treatment-naive disease, the overall response rate with pralsetinib was 78%, and overall survival was 50 months; and among those with prior platinum treatment, they were 63% and 40 months, respectively.6 Common Grade 3-4 events included anemia (21%), hypertension (15%), and decreased neutrophils (13%). Fatal adverse events occurred in three patients (pneumonia, interstitial lung disease, and rhabdomyolysis). Based on these data, we consider pralsetinib to be an acceptable option in RET fusion-positive advanced NSCLC. Disclaimer: This content is provided for reference purposes only and represents a portion of an UpToDate topic. This content is only accurate as of the date it was published. You may not rely on the above content, or any information cited here as being applicable to specific patient circumstances. All topics are continuously updated as new evidence becomes available and subject to our peer-review process. To ensure you are accessing the most current clinical information, subscribe to UpToDate today at go.uptodate.com/ot30 or sign into your existing UpToDate account if you are a current subscriber.